1. Introduction {#s0005}
===============

Transcriptomic-based computational drug repurposing (DR) tools, such as Connectivity Map \[[@bb0005]\] and L1000CDS^2^ \[[@bb0010]\], compare a disease-related gene expression profile with a number of stored existing expression profiles corresponding to cellular responses against a number of perturbations. Existing tools return lists of candidate repurposed drugs, which can be ordered by their inhibition score. The inhibition score describes the potentiality of a chemical substance to alter the perturbed gene signature state of a disease back to its "normal-healthy" values. Although the inhibition score might give insight onto the potency of a drug against a disease, it alone cannot guarantee success in a clinical trial. On the other hand, cheminformatics tools, such as ChemMine Tools \[[@bb0015]\] and programming packages such as Rcpi \[[@bb0020]\] and ChemmineR \[[@bb0025]\] can suggest drugs with similar structure and possibly similar mode of action to drugs with a-priori knowledge regarding their effectiveness either against a specific disease-related mechanism or against diseases with phenotypic similarity to the targeted disease. However, the derived similarity score is often not enough to deem a drug an appropriate candidate against a disease.

Other types of drug information are ought to be examined, like the candidate drug\'s functional relation to the disease and its binding affinity to any related-to-the-disease gene target as well as its drug-likeness evaluation based on structural rules that might categorize the drug inappropriate for clinical trials. In order to attain both the scoring implementation for these different drug aspects and provide a more meaningful ranking of the candidate repurposed drugs, we have developed the CoDReS (Composite Drug Reranking Score) web-based tool based on- and extending the initial methodology introduced in \[[@bb0030]\] in the following ways; CoDReS integrates information from updated biological databases, incorporates binding affinity scores between ligands and proteins, evaluates drug-likeness and presents structural similarities between input drugs and possible failed drugs that have already been tested against the queried disease in clinical trials. A summary figure of the CoDReS pipeline is depicted in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1CoDReS summary figure.Fig. 1

2. Tool Description {#s0010}
===================

2.1. Scoring Scheme {#s0015}
-------------------

A composite score (from here on referred to as CoDReS) is calculated, for each drug, as the normalized weighted sum of the initial a-priori score (aS) with a functional (FS) and a structural score (StS) as introduced below:$$\mathit{CoDReS}_{i} = \frac{w_{\mathit{aS}} \ast \mathit{aS}_{i} + w_{\mathit{FS}} \ast \mathit{FS}_{i} + w_{\mathit{StS}} \ast \mathit{StS}_{i}}{\max\mathit{CoDReS}},i = 1,\ldots,N\ \mathit{drugs}$$

The weights w~aS~, w~FS~ and w~StS~ are user-defined parameters that determine the desired influence of each part (a-priori, functional and structural scores respectively) to the final score and have equal default values. The a-priori scores can be uploaded by the user and are automatically normalized in the unit interval \[0, 1\] by dividing with the absolute maximum a-priori score.

The functional score requires the calculation of two different parameters:(i)the Confidence Score, which reflects the gene-disease association and(ii)the Ki, which is an inhibitory constant, measured in nM, and represents the reciprocal of the binding affinity between the inhibitor (drug) and the enzyme (target) \[[@bb0035]\]. The smaller the Ki, the greater the binding affinity.

The FS for each drug is calculated as the sum of the products of Confidence Score with the inverse value of Ki, for each gene target of the drug that has been related to the queried disease. Each drug\'s FS is finally normalized in \[0, 1\] by dividing with the maximum FS.$$\mathit{FS} = \frac{\sum\limits_{j = 1}^{\mathit{nGenes}}\mathit{Confidence}\mathit{Score}_{j} \bullet \frac{1}{\mathit{Ki}_{j}}}{\max\mathit{FS}}$$

The structural score calculates a substance\'s drug-likeness based on the Lipinski "rules of 5" \[[@bb0040]\] and Veber\'s rule \[[@bb0045]\]. According to the Lipinski rules, in order for a drug to be orally active in humans, it should conform to the following rules: (i) have ≤5 hydrogen bond donors, (ii) have ≤10 hydrogen bond acceptors, (iii) weigh \<500 Da and (iv) have an octanol-water partition coefficient (log P) ≤5. The Veber\'s rule further requires that the chemical substance (v) contains ≤ 10 rotatable bonds and (vi) its polar surface area does not exceed 140 Ǻ^2^ (angstrom^2^). The final StS for each drug is a value within the range \[0, 1\] calculated in the following way:$$\mathit{StS} = 1 - \frac{\mathit{numViolations}}{6}$$where "6" is the maximum number of structural rules that a drug might violate.

2.2. Development {#s0020}
----------------

The static components of the user interface (UI) of the CoDReS web-based application are developed in php, html, css (bootstrap) and javascript (ajax), while the dynamic components of the UI are refreshed via php and back-end R scripts. Several data-repositories have been downloaded, parsed and integrated into a MySQL database, which in turn serves the CoDReS web-based application. Information regarding the database releases, versions and links can be found on [Table 1](#t0005){ref-type="table"}.Table 1Information regarding resources integrated to CoDReS.Table 1Database NameLinkFileCurrent VersionLast UpdateBindingDB<https://www.bindingdb.org/bind/chemsearch/marvin/SDFdownload.jsp?all_download> [=]{.ul} [yes]{.ul}BindingDB_All_2019m1.tsv.zip--2019/02CheMBL[ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/latest/]{.ul}chembl_24_1\_mysql.tar.gz24.12018/06DGIdb[http://www.dgidb.org/downloads]{.ul}Interactions TSV3.0.22018/01DisGeNET[http://www.disgenet.org/downloads]{.ul}ALL gene-disease associations6.02019/02DrugBank<https://www.drugbank.ca/releases/latest#open-data>DrugBank Vocabulary5.1.22018/12<https://www.drugbank.ca/releases/latest#protein-identifiers>Drug Target Identifiers - All5.1.22018/12<https://www.drugbank.ca/releases/latest#structures>Structural External Links - All5.1.22018/12DrugCentral<http://drugcentral.org/download>Drug-target interaction10.42018/08HGNC<https://www.genenames.org/cgi-bin/download>Approved Symbol, Synonyms--2019/02repoDB<http://apps.chiragjpgroup.org/repoDB/>full repoDB dataset1.22017/07Uniprot<ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/idmapping/by_organism>HUMAN_9606_idmapping.dat--2019/02

CoDReS works with drug synonyms that have been downloaded from DrugBank \[[@bb0050]\]. DrugBank is a drug-centric online database that provides detailed information on drugs and their gene targets. The rest of the databases that were used in CoDReS that include drug names have been parsed and have had their drug names translated to DrugBank\'s usual names. DrugBank identifiers were also assigned to each input drug where applicable or an "unassigned" value was given otherwise. At the gene level, CoDReS works on gene synonyms that derive from the HGNC \[[@bb0055]\] database and every other database that contains gene identifiers, is parsed and translated according to the HGNC gene synonyms.

The backend of CoDReS is developed in R. The FS\'s first parameter, namely Confidence Score, is taken from DisGeNET \[[@bb0060]\] which is an online database linking genes to diseases by integrating information of various biological databases and giving a score to each interaction. The Ki value of a drug-protein pair is queried from BindingDB \[[@bb0065]\] which is another online database that contains data from experimentally validated binding affinities between proteins and ligands. To achieve the proper linking between the databases, we convert genes to proteins through Uniprot \[[@bb0070]\] and by querying BindingDB the proteins are linked to drug identifiers either from DrugBank or CheMBL \[[@bb0075]\]. If no Ki value is found for a drug-protein pair, the application uses the median Ki value (184) of BindingDB, instead of the average value (120523.41) which results from the database\'s outliers. Uniprot is an online knowledgebase that hosts annotated sequences of over 120 million proteins as well as provides protein visualization methods. CheMBL is another drug related database similar to DrugBank. The gene targets of the input drugs are found in the parsed DrugBank, DrugCentral \[[@bb0080]\] and DGIdb \[[@bb0085]\] databases.

The StS of each drug is calculated via the Rcpi package of R and requires a drug\'s molecular structure as input. Each molecular structure is extracted by its respective simplified molecular-input line-entry system (SMILES) type, which is a specification in form of a line notation for describing the structure of chemical species using short ASCII strings. CoDReS tries to either map DrugBank identifiers or CheMBL drug names to SMILES. For every violated rule (aforementioned Lipinski and Veber rules), a drug receives a "plus 1" violation score, with the lowest possible score being six violations. In case there was no SMILES for a specific drug, the candidate drug is assigned a "zero" StS score acting in a conservative manner by adopting the worst-case scenario presenting the max number of violations.

Another important aspect of the CoDReS tool, is that it highlights the highest ranked drugs of structural clusters, as exemplars, by applying an affinity propagation clustering via the R package APCluster \[[@bb0090]\] on the similarity matrix of the fingerprints of the input drugs. Specifically, the calcDrugFPSim function of the Rcpi package is used in order to calculate the similarity matrix with a compact *E*-State fragments fingerprint type and a tanimoto metric as arguments. The structural exemplars are presented as a good choice of disease inhibitors for further investigation, since different structural properties might target different biological mechanisms of a disease phenotype.

Finally, if there are clinical trials carried out for a disease that have led to failed drugs against a disease, the structural similarity between these compounds and the input list of drugs is measured. For this purpose, the online dataset of repoDB \[[@bb0095]\] has been parsed, keeping the suspended, terminated and withdrawn drugs for each disease identifier. The execution pipeline together with all the integrated databases and packages are depicted in [Fig. 2](#f0010){ref-type="fig"}.Fig. 2CoDReS integration scheme.Fig. 2

2.3. User Execution {#s0025}
-------------------

The user is required to upload a file containing the drug names and, optionally their respective a-priori scores, as might be acquired from a drug-repurposing tool. As soon as the input file is uploaded, a histogram and a distribution diagram of the input scores are generated ([Fig. 3](#f0015){ref-type="fig"}). The weights denoting the importance of the aS, FS and StS are user-selected and have equal default values. The user must then choose a disease from a select box with auto-complete functionality that hosts all DisGeNET diseases.Fig. 3Input score diagrams are drawn after the user uploads a drug list with their respective scores as returned by any drug repurposing tool.Fig. 3

The output of the CoDReS function is then rendered in tabular form and can be sorted, printed and downloaded either as plain text, csv, spreadsheet or pdf file. The main CoDReS output table consists of the CoDReS rank, the initial position of the input drugs, their input names, their DrugBank usual names and identifiers (or input name again and "unassigned" identifier respectively, if not found in DrugBank\'s synonyms list), their normalized score per category and their normalized CoDReS, by which they are sorted in descending order ([Fig. 4](#f0020){ref-type="fig"}). A drug-score diagram for each scoring parameter is also printed at the bottom of the page after the execution ([Fig. 5](#f0025){ref-type="fig"}).Fig. 4Main CoDReS output matrix.Fig. 4Fig. 5Drug score diagrams for each scoring parameter.Fig. 5

In case there are stated failed clinical trials in repoDB for the selected disease, a similarity matrix of all input drugs against the failed drugs is returned to the user, where the column names represent the failed drugs and the row names the input drugs ([Fig. 6](#f0030){ref-type="fig"}).Fig. 6Structural similarity of input drugs (rows) to clinically failed drugs of input disease (columns) as found in repoDB.Fig. 6

3. Results and Validation {#s0030}
=========================

To check the validity of the CoDReS results, we considered examples disregarding a-priori scores. We chose the top forty diseases from DisGeNET with the most correlated genes that have at least twenty drug candidates in Malacards \[[@bb0100]\]. These diseases are listed in [Table 2](#t0010){ref-type="table"}. For each disease, we created a mixture list of two hundred drugs: 95% randomly selected from DrugBank and 5% of the top drugs reported from Malacards repository as developed/used for the selected disease. After executing CoDReS for each experiment, we counted the number of the actual disease-related drugs that were found in the top 5% of the ranked drugs, based on their CoDReS along with a *p*-value calculated through a hypergeometric distribution test. We repeated this procedure a hundred times for each disease and then calculated the median, maximum, minimum and average *p*-value metrics for each disease. CoDReS ranked effectively (median *p*-value \<.05) the input drugs in 35/40 diseases. CoDReS failed to rank drugs correctly in five out of 40 diseases but this failure can be partially explained since the top ten drugs corresponding to most of these diseases contain abstract substances or generic categories such as "Anti-Inflammatory Agents", "Cytochrome P-450 Enzyme Inhibitors", "Immunologic Factors" or drugs with close to zero gene targets participating in the disease. The statistical results are presented in [Table 3](#t0015){ref-type="table"}.Table 2information on the diseases used for the validation; the two first columns present the disease\'s name and umls id respectively as found in disgenet, the third column the total genes that participate in the disease and the fourth column the disease\'s name as returned from malacards.Table 2Disease nameUMLS IDGene countMalacards nameMalignant neoplasm of breastC00061425053Breast CancerLiver carcinomaC22391763592Hepatocellular CarcinomaColorectal CancerC15272493298Colorectal CancerMalignant neoplasm of prostateC03763583238Prostate CancerCarcinoma of lungC06842492475Lung CancermelanomaC00252022453MelanomaMalignant neoplasm of stomachC00246232397Gastric CancerGliomaC00176382210GliomaOvarian CarcinomaC00299252202Ovarian CancerAlzheimer\'s DiseaseC00023951981Alzheimer DiseaseleukemiaC00234181940LeukemiaGlioblastomaC00176361936GlioblastomaSchizophreniaC00363411922SchizophreniaSquamous cell carcinomaC00071371875Squamous Cell CarcinomaPancreatic carcinomaC02359741868Pancreatic CancerRheumatoid ArthritisC00038731832Rheumatoid ArthritisAdenocarcinomaC00014181711AdenocarcinomaLeukemia, Myelocytic, AcuteC00234671702Leukemia, Acute MyeloidNeuroblastomaC00278191698NeuroblastomaDiabetes Mellitus, Non-Insulin-DependentC00118601671Diabetes Mellitus, Noninsulin-DependentDiabetes MellitusC00118491506Diabetes MellitusRenal Cell CarcinomaC00071341347Renal Cell Carcinoma, Papillary, 1AsthmaC00040961312AsthmaMultiple MyelomaC00267641311Myeloma, MultipleHypertensive diseaseC00205381309Hypertension, EssentialLymphomaC00242991306LymphomaBladder NeoplasmC00056951216Bladder CancerEpilepsyC00145441176EpilepsySeizuresC00365721173Seizure DisorderChronic Lymphocytic LeukemiaC00234341119Leukemia, Chronic LymphocyticLupus Erythematosus, SystemicC00241411112Systemic Lupus ErythematosusMultiple SclerosisC00267691105Multiple SclerosisCervix carcinomaC03025921104Cervix carcinomaOsteosarcomaC00294631102Osteogenic SarcomaArteriosclerosisC00038501086ArteriosclerosisAutoimmune DiseasesC00043641059Autoimmune DiseaseOsteosarcoma of boneC05854421041Bone OsteosarcomaSquamous cell carcinoma of esophagusC02796261022Esophagus Squamous Cell CarcinomaAdenomaC0001430999AdenomaCoronary Artery DiseaseC1956346980Coronary Artery AnomalyTable 3The median, maximum, minimum and average *p*-value results of 100 codres executions for each disease as calculated by hypergeometric distribution tests. The median *p*-values that are above 0.05 are painted red.Table 3

4. Discussion {#s0035}
=============

In this article we present CoDReS, a drug (re-)ranking tool that can act as a tool for post filtering drug lists generated either by conventional drug repurposing tools or by any other drug discovery pipeline. CoDReS should be used as a means of suggesting the best candidates for in vitro or clinical studies by combining a priori knowledge with functional and structural information. The in silico validation schema of CoDReS, as presented in the previous paragraph, brought the disease-related drugs to the top of the random drug pool in almost every case. Despite the promising results, this schema is only a computational validation of the tool\'s capabilities. In the end, the scientists using the tool should always incorporate their knowledge, expertise and the bibliography in order to decide the best drug candidates for further experiments.
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